Xenon Pharmaceuticals Inc (NASDAQ: XENE) has reported E.P.S. of $-0.64 for its fourth fiscal quarter (ending December 31) versus $-0.57 for the same period a year ago. Relative to the consensus estimate of $-0.76, this was a premium of $0.12. For the latest four quarters through December 31, E.P.S. were $-2.73 compared to $-2.06 a year ago.
Recent Price Action
On 2/29/24, Xenon Pharmaceuticals Inc (NASDAQ: XENE) stock declined modestly by -1.3%, closing at $47.20. Moreover, this decline was accompanied by above average trading volume at 138% of normal. The stock has declined -3.3% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
XENE is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Xenon Pharmaceuticals has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Xenon Pharmaceuticals has a very low Appreciation Score of 9 but a good Power Rating of 77, and the Negative Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment